Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

se of $3,000. Higher legal, audit and consulting fees in the first quarter of fiscal 2009 were offset by lower wages due to the one time charge of $434,000 relating to the resignation of the Company's Chairman in the first quarter of fiscal 2008.

Amortization of intangible and capital assets

Amortization of intangible assets in the first quarter of fiscal 2009 totaled $3,000 (2008 - $7,000). Amortization of capital assets in the first quarter of fiscal 2009 totaled $64,000 (2008 - $66,000).

Stock-based compensation

Stock-based compensation expense in the first quarter of fiscal 2009 totaled $nil (2008 - $12,000). The stock-based compensation expense in the first quarter of fiscal 2008 relates to the ongoing amortization of compensation costs of stock options granted on June 30, 2005, over their vesting period.

Interest income

Interest income in the first quarter of fiscal 2009 totaled $205,000 (2008 - $104,000) and is mainly the result of higher cash balances.

Foreign exchange loss

Foreign exchange losses in the first quarter of fiscal 2009 totaled $150,000 (2008 - $108,000). Foreign exchange losses are mainly the result of the foreign currency translation of the Company's integrated foreign operation in Ireland. The net assets in Ireland consist mainly of cash and cash equivalents, denominated in Euro dollars, which are used to fund clinical trials of Topical Interferon Alpha-2b in Europe. In addition, U.S. dollar purchases of inventory for distribution in Canada also contributed to the foreign exchange loss.

Income taxes

Income tax expense in the first quarter of fiscal 2009 totaled $30,000 (2008 - $32,000). All income taxes are attributable to the Company's operations in Ireland.

cash flow

Operating activities

N
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... and MENLO PARK, Calif. , April ... DMPI) (DelMar and the Company), a biopharmaceutical company focused ... orphan drug indications, today announced that the Mayo ... clinical trial site for the ongoing, multicenter Phase I/II ... (GBM), the most common and deadly form of human ...
(Date:4/16/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... DCVax® personalized immune therapies for cancer, announced today ... Cancer Immunotherapy Index (LCINDX), a professional index recently ... field within the biotechnology space.  ... companies" in the immunotherapy space, including 6 big ...
(Date:4/16/2015)... Tex. (PRWEB) April 16, 2015 ... chain management systems for highly regulated industries, is ... been name a monthly columnist for Cold Chain ... ( http://www.coldchainiq.com ). His column titled, Global Cold ... chain information for today’s life sciences, pharmaceutical and ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... April 12, 2011 Reportlinker.com announces that a new ... Biomarker Partnering Terms and Agreements ... The Biomarker Partnering Terms and Agreements report ... partnering deals and agreements entered into by the worlds ...
... April 11, 2011 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... that it has executed a binding letter of intent ... biomedical instrumentation and microfluidics company with global distribution for ... The transaction highlights are: Shrink ...
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... development, manufacture and sale of enzyme and protein ... industries, today announced that its President and Chief ... Advanced Biofuels Leadership Conference taking place from April ...
Cached Biology Technology:Reportlinker Adds Biomarker Partnering Terms and Agreements 2Reportlinker Adds Biomarker Partnering Terms and Agreements 3Reportlinker Adds Biomarker Partnering Terms and Agreements 4Reportlinker Adds Biomarker Partnering Terms and Agreements 5Reportlinker Adds Biomarker Partnering Terms and Agreements 6Reportlinker Adds Biomarker Partnering Terms and Agreements 7Reportlinker Adds Biomarker Partnering Terms and Agreements 8Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 2Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 3Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 4Dyadic International to Present at Advanced Biofuels Leadership Conference 2
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... 17, 2015 Emotient, the leader in ... announced general availability of Emotient Analytics , ... analysis of facial expressions. The system analyzes videos ... products and services. It delivers audience response metrics ... - as derived from facial evidence of emotional ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... discovery made by researchers at the Institut de recherches ... Di Noia, Director of the Mechanisms and Genetic Diversity ... Journal of Experimental Medicine . The team identified a ... for the therapy of some types of lymphoma and ...
... State University are developing a cost-effective electronic monitoring system ... critical coastal ecosystems by allowing users to track water-quality ... support from a National Science Foundation (NSF) grant. ... to monitor environmental conditions in the Chesapeake Bay, the ...
... London, UK (November 1, 2010) In April 2010, ... on the conclusion that the current missile defense systems will ... of nuclear-armed combat. Now research in the Bulletin of ... have not been tested against real-world threats and would not ...
Cached Biology News:A discovery could be important for the therapy of lymphoma and leukemia 2Researchers developing real-time electronic monitoring for coastal waters 2US nuclear safety claim is a 'dangerous fantasy' 2US nuclear safety claim is a 'dangerous fantasy' 3